Your browser is no longer supported. Please, upgrade your browser.
Virios Therapeutics, LLC
Index- P/E- EPS (ttm)-1.16 Insider Own10.80% Shs Outstand9.72M Perf Week-8.87%
Market Cap40.82M Forward P/E- EPS next Y- Insider Trans2.53% Shs Float6.18M Perf Month-21.87%
Income-10.30M PEG- EPS next Q- Inst Own7.60% Short Float2.11% Perf Quarter-34.70%
Sales- P/S- EPS this Y-294.50% Inst Trans4.66% Short Ratio1.20 Perf Half Y-
Book/sh3.08 P/B1.60 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh3.60 P/C1.37 EPS next 5Y- ROE- 52W Range4.60 - 16.71 Perf YTD-34.35%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-70.50% Beta-
Dividend %- Quick Ratio20.50 Sales past 5Y- Gross Margin- 52W Low7.17% ATR0.34
Employees3 Current Ratio20.50 Sales Q/Q- Oper. Margin- RSI (14)36.49 Volatility5.61% 6.46%
OptionableNo Debt/Eq0.00 EPS Q/Q-720.10% Profit Margin- Rel Volume0.08 Prev Close4.90
ShortableYes LT Debt/Eq0.00 EarningsMay 13 BMO Payout- Avg Volume108.89K Price4.93
Recom- SMA20-10.37% SMA50-13.93% SMA200-28.49% Volume8,679 Change0.61%
May-07-21 07:05AM  
May-06-21 07:05AM  
Apr-16-21 07:05AM  
Apr-07-21 07:05AM  
Mar-30-21 09:29AM  
Mar-18-21 07:05AM  
Mar-11-21 07:05AM  
Feb-24-21 07:05AM  
Feb-01-21 07:05AM  
Jan-04-21 04:05PM  
Dec-21-20 03:00PM  
Dec-17-20 11:59AM  
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duncan Gregory ScottChief Executive OfficerApr 06Buy6.363822,42919,961Apr 07 01:59 PM
Duncan Gregory ScottChief Executive OfficerApr 05Buy6.1715,67596,75719,579Apr 06 03:38 PM
Pridgen WilliamDirectorJan 29Buy7.473,50026,1453,500Feb 01 07:54 PM
Keefer David RDirectorJan 28Option Exercise7.801,60212,4967,808Feb 01 07:54 PM
Pridgen WilliamDirectorJan 28Option Exercise7.808016,248727,993Feb 01 07:54 PM
Walsh AngelaVP of FinanceJan 28Buy7.301,0007,3001,000Feb 01 07:54 PM
Duncan Gregory ScottChief Executive OfficerJan 06Option Exercise7.808016,2483,904Jan 08 07:23 PM
Pridgen WilliamDirectorDec 17Buy11.981,50017,970727,192Dec 21 08:10 PM